Sutro Biopharma (STRO) Non-Current Deffered Revenue (2017 - 2025)

Sutro Biopharma has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $2.0 million in Q4 2025.

• Quarterly Non-Current Deffered Revenue fell 83.82% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 83.82% YoY) and the FY2025 annual result came in at $2.0 million, down 83.82% from the prior year.
• Non-Current Deffered Revenue fell to $2.0 million in Q4 2025 per STRO's latest filing, from $3.8 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $90.0 million in Q2 2022 and troughed at $145000.0 in Q3 2021.
• A 5-year average of $37.5 million and a median of $19.8 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2022: Non-Current Deffered Revenue plunged 98.27% in 2021, then soared 51439.31% in 2022.
• Over 5 years, Non-Current Deffered Revenue stood at $145000.0 in 2021, then jumped by 61889.66% to $89.9 million in 2022, then sank by 40.61% to $53.4 million in 2023, then sank by 76.52% to $12.5 million in 2024, then slumped by 83.82% to $2.0 million in 2025.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.0 million, $3.8 million, and $6.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.